Latham & Watkins, O'Melveny & Myers advise in genome mapping deal with California counsel
Mountain View-based life sciences company Complete Genomics Inc. and China-based competitor BGI-Shenzhen announced Monday that a U.S. subsidiary of BGI will purchase all shares of Complete Genomics at $3.15 per share, valuing the deal at approximately $117.6 million. Under a separate agreement, Complete Genomic...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In